AbbVie After Purchase Apogee? Is It a Buy Now for Investors
AbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
Investors follow market indices to gauge performance, set expectations, and benchmark risk. Indices provide a common frame for evaluating results.
28,426 articlesAbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
Rocket Lab is pursuing a bold $8 billion strategy to merge rocket launches, satellites, and data services. Learn what...
Tech stocks swung wildly midday as traders dumped riskier names, then rotated into consumer staples and paints. By da...
SoFi stock fell last month, sparking questions about the growth story and valuation. This article breaks down the fac...
SpaceX finally opened its doors to public markets, signaling a pivotal moment for growth investors. This guide breaks...
XDTE uses daily 0DTE call selling to generate income from the S&P 500. This piece explains how the fund works, what i...
MAGY, the MAGY Magnificent Seven Covered Call ETF, now offers a Monday-morning income payout. The fund uses an active...
Strategy’s perpetual preferred stock has fallen from the $100 issuance price to the mid-$70s, prompting widespread in...
Ciena’s stock tumbling taking center stage as its latest earnings signals weigh on the broader optical-networking spa...
A potential shift away from the Fed’s traditional guidance could redefine how markets price risk. If kevin warsh read...
When you’re building a global equity sleeve, two popular choices stand out: Vanguard VT and the SPDR Portfolio Develo...
As we reach the halfway point of 2026, certain S&P 500 members are leading the pack with impressive gains. This artic...